<DOC>
	<DOCNO>NCT00001901</DOCNO>
	<brief_summary>This study examine use etanercept ( also call Enbrel TNFR : Fc ) patient Wegener 's granulomatosis , type vasculitis ( blood vessel inflammation ) . Wegener 's granulomatosis may affect many part body , include brain , nerve , eye , sinus , lung , kidney , intestinal tract , skin , joint , heart , site . Generally , great disease involvement , life-threatening . Standard treatment combination prednisone cytotoxic agent-usually cyclophosphamide methotrexate . However , many patient treat regimen disease relapse , others take drug severe side effect . This study evaluate etanercept 's safety effectiveness , particularly value reduce need prednisone prevent disease relapse . The Food Drug Administration approve etanercept treat rheumatoid arthritis , another inflammatory disease . The drug work block activity TNF-a protein make white blood cell involve inflammatory process . Since prednisone also affect inflammatory protein lower TNF production , use etanercept may reduce need prednisone patient Wegener 's granulomatosis , thus risk side effect . Patients 10 70 year age Wegener 's granulomatosis never take prednisone , methotrexate cyclophosphamide , take drug less 3 week may eligible study . Participants medical history review physical examination , include laboratory study . If medically indicate , X-rays , consultation biopsy ( surgical removal small tissue sample ) affect organ also do . All patient begin treatment prednisone , methotrexate etanercept . Those improve regimen stop prednisone gradually 3 month . Those achieve disease remission end another 3 month randomly assign either continue take etanercept methotrexate another 12 month stop etanercept continue methotrexate next 12 month ( methotrexate gradually stop ) . Patients remission 6-month point continue take etanercept go remission , assign stop stop etanercept , describe . Patients achieve remission within 12 month begin treatment take study . Patients disease relapse study likely switch treatment prednisone either methotrexate cyclophosphamide . Patients randomize stop etanercept relapse within year stop drug may offer re-treatment protocol , continue etanercept full year remission . Patients evaluate outpatient clinic every 2 4 week first 4 month every 1 3 month . Patients whose disease remission stop medication follow every 3 6 month 2 year . Follow-up evaluation include physical examination , blood draw , medically indicate , X-rays . The total study duration 60 70 month .</brief_summary>
	<brief_title>Etanercept Treat Wegener 's Granulomatosis</brief_title>
	<detailed_description>The purpose study assess safety , pharmacokinetics , immunologic effect recombinant fusion protein consist soluble tumor necrosis factor receptor link Fc portion human IgG1 ( TNFR : Fc ) patient Wegener 's granulomatosis . A secondary objective determine TNFR : Fc demonstrate anti-inflammatory activity treatment Wegener 's granulomatosis . Specifically , seek examine whether TNFR : Fc able reduce need glucocorticoid treatment low relapse rate . Patients eligible participate protocol evidence disease active immediately life-threatening . In study , patient receive TNFR : Fc ( 25mg subcutaneously twice weekly ) together methotrexate prednisone . In patient prednisone tapered 3 month schedule . At end 6 month , patient remission randomize either continue TNFR : Fc another 12 month stop . All patient continue methotrexate 1 year enter remission time taper discontinue .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>INCLUSION CRITERIA : Documentation Wegener 's granulomatosis base clinical characteristic histopathologic and/or angiographic evidence vasculitis . In absence histopathologic and/or angiographic evidence vasculitis , patient meet one follow criterion infectious autoimmune disease may mimic Wegener 's granulomatosis relate systemic vasculitides exclude also eligible : ) positive assay antineutrophil cytoplasmic autoantibody ( C PANCA ) presence glomerulonephritis define red blood cell cast proteinuria renal biopsy show necrotizing glomerulonephritis absence immune deposit ; b ) positive assay antineutrophil cytoplasmic autoantibody ( C PANCA ) presence granulomatous inflammation biopsy plus abnormal chest radiograph ( define presence nodule , fix infiltrates , cavity ) plus nasal/oral inflammation clinical examination . Subjects must age 10 70 year . Subject must evidence active major organ disease . Patients never previously see NIH eligible condition meet either : receiving treatment ; receive prednisone induction dose MTX le 3 week ; receive prednisone induction dose CYC le 3 week severe disease . EXCLUSION CRITERIA : Patients evidence bacterial sepsis . Patients evidence active systemic infection judgment investigator , great danger patient underlie vasculitis . Pregnant subject nurse infant . Fertile woman must negative pregnancy test within one week prior study entry participant must use effective mean birth control . Patients one follow : serum creatinine great 2.5 mg/dl creatinine clearance le 35 ml/min ; pulmonary disease result pO ( 2 ) less 70 mmHg , FVC , FEV ( 1 ) DLCO le 70 % predict ; Wegener 's granulomatosisrelated disease manifestation , judgment investigator , immediately lifethreatening . Hemocytopenia : platelet count le 80,000/mm ( 3 ) , leukocyte count le 3,000/mm ( 3 ) , hematocrit less 20 % ( absence gastrointestinal bleeding hemolytic anemia ) . Liver function test abnormality great three time upper limit normal ( either serum GOT , GPT , alkaline phosphatase , and/or bilirubin ) . Processes associate increased risk MTX toxicity : acute chronic liver disease , past history alcohol abuse ( great 14 oz . 100 proof liquor equivalent per week ) , ongoing alcohol use volume discontinue upon entry study . Serological evidence infection human immunodeficiency virus , hepatitis C , positive hepatitis B surface antigen . A serological determination perform within two week begin study participation . Treatment investigational drug within 30 day . Known allergy TNFR : Fc . Individuals history psychiatric illness opinion principal investigator ( PI ) would preclude entrance study . History multiple sclerosis demyelinate disease .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>Vasculitis</keyword>
	<keyword>Prednisone-sparing</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Tumor Necrosis Factor</keyword>
	<keyword>Remission</keyword>
	<keyword>Wegener 's Granulomatosis</keyword>
</DOC>